Showing results (861-870 of 6,303) with videos related to

Sort By:
Pageof 631
Diabetes, Obesity & Metabolism|March 17, 2021
The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden: A health economic modelling analysis based on nationwide dataMargareta Hellgren, Ann-Marie Svensson, Stefan Franzén, et al.
Diabetes, Obesity & Metabolism|January 27, 2021
Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2Simone Bastrup Israelsen, Anton Pottegård, Håkon Sandholdt, et al.
Diabetes, Obesity & Metabolism|January 27, 2021
Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOMESubodh Verma, C David Mazer, Silvio E Inzucchi, et al.
Diabetes, Obesity & Metabolism|January 19, 2021
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetesJonathan M Wilson, Amir Nikooienejad, Deborah A Robins, et al.
Diabetes, Obesity & Metabolism|January 19, 2021
HbA1c and brain health across the entire glycaemic spectrumVictoria Garfield, Aliki-Eleni Farmaki, Sophie V Eastwood, et al.
Diabetes, Obesity & Metabolism|November 8, 2021
Restrictive versus liberal transfusion in patients with diabetes undergoing cardiac surgery: An open-label, randomized, blinded outcome evaluation trialNikhil Mistry, Nadine Shehata, Paula Carmona, et al.
Diabetes, Obesity & Metabolism|March 12, 2021
Pilots flying with insulin-treated diabetesDavid L Russell-Jones, Ewan J Hutchison, Graham A Roberts
Diabetes, Obesity & Metabolism|March 9, 2021
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trialGeremia B Bolli, Alice Cheng, Bernard Charbonnel, et al.
Diabetes, Obesity & Metabolism|January 29, 2021
A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic controlTakashi Kadowaki, Yutaka Seino, Kohei Kaku, et al.
Diabetes, Obesity & Metabolism|February 2, 2021
Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trialAhmad Haidar, Jean-Francois Yale, Leif Erik Lovblom, et al.
Pageof 631